Cargando…
Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
BACKGROUND: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242225/ https://www.ncbi.nlm.nih.gov/pubmed/16171525 http://dx.doi.org/10.1186/1471-230X-5-30 |
_version_ | 1782125617370628096 |
---|---|
author | Gur, Ali Dikici, Bünyamin Nas, Kemal Bosnak, Mehmet Haspolat, Kenan Sarac, Aysegul Jale |
author_facet | Gur, Ali Dikici, Bünyamin Nas, Kemal Bosnak, Mehmet Haspolat, Kenan Sarac, Aysegul Jale |
author_sort | Gur, Ali |
collection | PubMed |
description | BACKGROUND: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B treated with IFN-alpha. METHODS: BMD, levels of parathyroid hormone (PTH), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), calcium, alkaline phosphates (ALP), cytokines as TNF-alpha, interleukin (IL)-1(β), IL-2r, IL-6, and IL-8 were studied in 54 children with chronic hepatitis B (4–15 years old) treated with interferon alone (n = 19) or in combination with lamivudine (n = 35) for six months and as controls in 50 age-matched healthy children. RESULTS: There was no significant difference in respect to serum IL-1(β), TNF-α and osteocalcin levels while serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p = 0.013), PTH (p = 0.029), and CTX (p = 0.021) levels were higher in children with chronic hepatitis B than in healthy controls. BMD of femur neck (p = 0.012) and trochanter (p = 0.046) in patients were higher than in healthy controls. There was a statistically significant correlation between serum IL-1(β )and osteocalcin (r = -0.355, p < 0.01); between serum IL-8 and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361, p = 0.01); between serum ALP and femur neck BMD (r = 0.303, p = 0.05), and trochanter BMD (r = 0.365, p = 0.01); between spine BMD and IL-2R (r = -0.330, p < 0.05). CONCLUSION: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine than in healthy children. High femur BMD measurements found in patients may suggest that IFN-alpha therapy in children with chronic hepatitis B could contribute indirectly to prevent from hip osteoporosis. Additionally, further investigations on effects of IFN-alpha for bone structure in children should be performed in the future. |
format | Text |
id | pubmed-1242225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-12422252005-10-06 Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? Gur, Ali Dikici, Bünyamin Nas, Kemal Bosnak, Mehmet Haspolat, Kenan Sarac, Aysegul Jale BMC Gastroenterol Research Article BACKGROUND: Our aim was to determinate bone mineral density (BMD), levels of biochemical markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B treated with IFN-alpha. METHODS: BMD, levels of parathyroid hormone (PTH), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), calcium, alkaline phosphates (ALP), cytokines as TNF-alpha, interleukin (IL)-1(β), IL-2r, IL-6, and IL-8 were studied in 54 children with chronic hepatitis B (4–15 years old) treated with interferon alone (n = 19) or in combination with lamivudine (n = 35) for six months and as controls in 50 age-matched healthy children. RESULTS: There was no significant difference in respect to serum IL-1(β), TNF-α and osteocalcin levels while serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p = 0.013), PTH (p = 0.029), and CTX (p = 0.021) levels were higher in children with chronic hepatitis B than in healthy controls. BMD of femur neck (p = 0.012) and trochanter (p = 0.046) in patients were higher than in healthy controls. There was a statistically significant correlation between serum IL-1(β )and osteocalcin (r = -0.355, p < 0.01); between serum IL-8 and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361, p = 0.01); between serum ALP and femur neck BMD (r = 0.303, p = 0.05), and trochanter BMD (r = 0.365, p = 0.01); between spine BMD and IL-2R (r = -0.330, p < 0.05). CONCLUSION: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or combination with lamivudine than in healthy children. High femur BMD measurements found in patients may suggest that IFN-alpha therapy in children with chronic hepatitis B could contribute indirectly to prevent from hip osteoporosis. Additionally, further investigations on effects of IFN-alpha for bone structure in children should be performed in the future. BioMed Central 2005-09-19 /pmc/articles/PMC1242225/ /pubmed/16171525 http://dx.doi.org/10.1186/1471-230X-5-30 Text en Copyright © 2005 Gur et al; licensee BioMed Central Ltd. |
spellingShingle | Research Article Gur, Ali Dikici, Bünyamin Nas, Kemal Bosnak, Mehmet Haspolat, Kenan Sarac, Aysegul Jale Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? |
title | Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? |
title_full | Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? |
title_fullStr | Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? |
title_full_unstemmed | Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? |
title_short | Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? |
title_sort | bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis b: does interferon therapy prevent from osteoporosis? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242225/ https://www.ncbi.nlm.nih.gov/pubmed/16171525 http://dx.doi.org/10.1186/1471-230X-5-30 |
work_keys_str_mv | AT gurali bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis AT dikicibunyamin bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis AT naskemal bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis AT bosnakmehmet bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis AT haspolatkenan bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis AT saracayseguljale bonemineraldensityandcytokinelevelsduringinterferontherapyinchildrenwithchronichepatitisbdoesinterferontherapypreventfromosteoporosis |